COVID-19 vaccines: the importance of transparency and fact-based education

Br J Clin Pharmacol. 2020 Nov;86(11):2107-2110. doi: 10.1111/bcp.14581. Epub 2020 Oct 14.

Adam F Cohen¹, Joop van Gerven^{2

3}, Juan Garcia Burgos⁴, Anthonius de Boer⁵, Ron A M Foucher⁶, H Flore⁷, Zvi Teitelbaum⁸, Willem van Eden^{9

10}, Andrew Webb¹¹, Serge Cremers¹²

¹ Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
² Central Committee for Human Research (CCMO) and Competent Trial Authority of The Netherlands, The Hague, The Netherlands.
³ Faculty of Medicine, Division of Neurology, Leiden University, Leiden, The Netherlands.
⁴ Stakeholders and Public Engagement Department, European Medicines Agency, Amsterdam, The Netherlands.
⁵ Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Scienes, Utrecht University, Utrecht, The Netherlands.
⁶ Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
⁷ HAL Allergy Group, Leiden, The Netherlands.
⁸ Section of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel.
⁹ Faculty of Veterinary Medicine, Department of Biomolecular Health Sciences - Infectious Diseases & Immunology, Utrecht University, Utrecht, The Netherlands.
¹⁰ CSO Trajectum Pharma, Utrecht, The Netherlands.
¹¹ Faculty of Life Sciences & Medicine, Department of Vascular Risk & Surgery, King's College London, London, UK.
¹² Department of Pathology & Cell Biology, Division of Laboratory Medicine, Columbia University, New York.

No abstract available

Publication types